Real-time Estimate
Cboe BZX
16:40:59 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
3.835
USD
|
+1.99%
|
|
-4.61%
|
-33.01%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
10,832
|
4,027
|
2,898
|
1,657
|
1,101
|
-
|
-
|
Enterprise Value (EV)
1 |
10,240
|
3,304
|
2,012
|
1,595
|
917.6
|
1,022
|
976.5
|
P/E ratio
|
89.4
x
|
29.8
x
|
20.3
x
|
-11.2
x
|
-6.21
x
|
-6.04
x
|
-5.08
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
46.5
x
|
10.7
x
|
5.97
x
|
43.6
x
|
23
x
|
17.1
x
|
13.5
x
|
EV / Revenue
|
43.9
x
|
8.8
x
|
4.14
x
|
41.9
x
|
19.2
x
|
15.9
x
|
12
x
|
EV / EBITDA
|
63.7
x
|
15.1
x
|
8.23
x
|
-7.49
x
|
-4.22
x
|
-5.12
x
|
-3.87
x
|
EV / FCF
|
787
x
|
17.7
x
|
9.73
x
|
-13.2
x
|
-5.2
x
|
-6.53
x
|
-
|
FCF Yield
|
0.13%
|
5.63%
|
10.3%
|
-7.58%
|
-19.2%
|
-15.3%
|
-
|
Price to Book
|
13.1
x
|
3.84
x
|
2.36
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
269,188
|
281,581
|
286,100
|
290,170
|
292,782
|
-
|
-
|
Reference price
2 |
40.24
|
14.30
|
10.13
|
5.710
|
3.760
|
3.760
|
3.760
|
Announcement Date
|
29/03/21
|
24/02/22
|
21/02/23
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11.61
|
233.2
|
375.2
|
485.4
|
38.02
|
47.81
|
64.33
|
81.38
|
EBITDA
1 |
-
|
160.9
|
218.9
|
244.4
|
-212.8
|
-217.2
|
-199.6
|
-252.2
|
EBIT
1 |
-
|
156
|
204.4
|
216.5
|
-237.2
|
-239.7
|
-244
|
-244.8
|
Operating Margin
|
-
|
66.92%
|
54.48%
|
44.6%
|
-623.82%
|
-501.27%
|
-379.37%
|
-300.77%
|
Earnings before Tax (EBT)
1 |
-
|
157.8
|
219.1
|
239.1
|
-174
|
-207.9
|
-236.5
|
-222.3
|
Net income
1 |
-
|
118.9
|
153.5
|
158.5
|
-146.4
|
-190.3
|
-218.6
|
-222.3
|
Net margin
|
-
|
51%
|
40.9%
|
32.66%
|
-385%
|
-398.02%
|
-339.86%
|
-273.14%
|
EPS
2 |
-0.1500
|
0.4500
|
0.4800
|
0.5000
|
-0.5100
|
-0.6056
|
-0.6229
|
-0.7400
|
Free Cash Flow
1 |
-
|
13.02
|
186.1
|
206.7
|
-120.8
|
-176.4
|
-156.5
|
-
|
FCF margin
|
-
|
5.58%
|
49.61%
|
42.58%
|
-317.75%
|
-368.94%
|
-243.29%
|
-
|
FCF Conversion (EBITDA)
|
-
|
8.09%
|
85.04%
|
84.59%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
10.95%
|
121.29%
|
130.39%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/10/20
|
29/03/21
|
24/02/22
|
21/02/23
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
5.508
|
139.3
|
316.6
|
45.92
|
101.4
|
21.54
|
12.19
|
10.06
|
6.599
|
9.2
|
10.85
|
11.52
|
12.04
|
13
|
19.18
|
EBITDA
1 |
-24.43
|
85.53
|
228.9
|
-3.499
|
42.88
|
-23.96
|
-59.36
|
-
|
-
|
-55.71
|
-52.2
|
-54.2
|
-51.6
|
-48.7
|
-41.3
|
EBIT
1 |
-28.1
|
81.55
|
225
|
-8.396
|
37.74
|
-37.78
|
-64.87
|
-51.39
|
-54.89
|
-66.05
|
-60.25
|
-59.83
|
-59.08
|
-59.25
|
-55.57
|
Operating Margin
|
-510.09%
|
58.53%
|
71.06%
|
-18.29%
|
37.22%
|
-175.34%
|
-532.1%
|
-511.03%
|
-831.79%
|
-717.97%
|
-555.14%
|
-519.46%
|
-490.61%
|
-455.87%
|
-289.72%
|
Earnings before Tax (EBT)
1 |
-24.97
|
84.71
|
230.8
|
-6.886
|
46.59
|
-31.41
|
-48.15
|
-38
|
-39.28
|
-48.6
|
-51.89
|
-52.3
|
-51.8
|
-52.31
|
-55.56
|
Net income
1 |
-21.38
|
59.95
|
168.6
|
-6.785
|
26.62
|
-29.89
|
-40.11
|
-30.53
|
-28.61
|
-47.2
|
-48.13
|
-48.38
|
-47.64
|
-49.14
|
-55.56
|
Net margin
|
-388.16%
|
43.03%
|
53.25%
|
-14.78%
|
26.26%
|
-138.75%
|
-328.99%
|
-303.58%
|
-433.55%
|
-513.04%
|
-443.39%
|
-420.06%
|
-395.55%
|
-378.03%
|
-289.71%
|
EPS
2 |
-0.0800
|
0.1900
|
0.5400
|
-0.0200
|
0.0800
|
-0.1000
|
-0.1400
|
-0.1100
|
-0.1000
|
-0.1600
|
-0.1533
|
-0.1467
|
-0.1456
|
-0.1489
|
-0.1450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
24/02/22
|
10/05/22
|
09/08/22
|
08/11/22
|
21/02/23
|
04/05/23
|
03/08/23
|
02/11/23
|
20/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
592
|
723
|
886
|
62.1
|
183
|
79.3
|
124
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
13
|
186
|
207
|
-121
|
-176
|
-157
|
-
|
ROE (net income / shareholders' equity)
|
-
|
28.3%
|
16.5%
|
14%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
3.080
|
3.720
|
4.300
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
0.0900
|
0.7700
|
0.8800
|
-0.2000
|
-
|
-
|
-
|
Capex
|
-
|
9.67
|
58.5
|
70.7
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
4.15%
|
15.58%
|
14.56%
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/10/20
|
29/03/21
|
24/02/22
|
21/02/23
|
20/02/24
|
-
|
-
|
-
|
Last Close Price
3.76
USD Average target price
14.75
USD Spread / Average Target +292.29% Consensus |
1st Jan change
|
Capi.
|
---|
| -33.01% | 1.1B | | +2.17% | 42.75B | | +47.64% | 41.61B | | +12.32% | 41.34B | | -12.36% | 26.59B | | +8.28% | 25.49B | | -23.21% | 18.12B | | +30.25% | 12.24B | | -1.32% | 11.76B | | +8.43% | 11B |
Other Biotechnology & Medical Research
|